First peripheral drug-eluting stent clinical results from China: 1-year outcomes of the Zilver PTX China study.

The benefit of using the Zilver PTX drug-eluting stent (DES) in superficial femoral artery (SFA) lesions has been demonstrated in multiple clinical studies. This prospective, multicenter study evaluated the 1-year safety and effectiveness of the DES for the treatment of femoropopliteal lesions in a Chinese patient population. Patients with a single In this study, 178 patients with symptomatic peripheral artery disease were enrolled at nine institutions in China. The average lesion length was 79.0 ± 48.6 mm (range 14.8-245.4 mm) and 50.0% of lesions were total occlusions. The 1-year primary patency rate was 81.9%. Covariate analysis revealed that lesion length ( This study showed promising short-term results for the treatment of SFA lesions with Zilver PTX DES in Chinese patients. ClinicalTrials.gov, identifier: NCT02171962.

Informations de copyright

Copyright © 2022 Ye, Böhme, Fu, Liu, Zhang, Liu, Zhang, Zou, Lu, Lottes, O'Leary, Zeller and Dake.

Déclaration de conflit d'intérêts

AEL and MDD are paid consultants for Cook Medical. EEO'L is a paid employee of Cook Medical. TZ has received honoraria from Abbott Vascular, Veryan, Biotronik, Boston Scientific Corp., Cook Medical, Gore and Associates, Medtronic, Philips-Spectranetics, and Shockwave; consulted for Boston Scientific Corp., Gore and Associates, Medtronic, Veryan, Intact Vascular, Shockwave, Bayer, and Vesper Medical; received (institution) research, clinical trial, or drug study funds from 480 biomedical, Bard Peripheral Vascular, Veryan, Biotronik, Efemoral, Cook Medical, Gore and Associates, Medtronic, Philips, Terumo, TriReme, Shockwave, Med Alliance, Intact Vascular, and B. Braun; and has common stock in QT Medical. This study was sponsored by Cook Medical. The funder had the following involvement with the study: study design, collection of data, analysis and interpretation of data, decision to publish the data, and writing the publication. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.